Pharma-Bio Serv (PBSV) Cash from Investing Activities (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly Cash from Investing Activities came in at -$1.9 million in Q2 2026, up 41.52% on a YoY basis from -$1.3 million in Q2 2025, and down 168.21% quarter-over-quarter from $2.8 million in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported Cash from Investing Activities for 17 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Investing Activities rose 41.52% year-over-year to -$1.9 million; the trailing twelve-month figure through Apr 2026 stood at $1.7 million (up 1.77% YoY), and the FY2025 full-year result was -$1.5 million, down 7.75% from the prior year.
- Cash from Investing Activities eased to -$1.9 million in Q2 2026 per PBSV's latest filing, from $2.8 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $7.3 million in Q4 2023 and bottomed at -$8.2 million in Q1 2023.
- Historically, Cash from Investing Activities has averaged -$343625.2 across 5 years, with a median of -$3224.0 in 2022.
- The widest YoY moves for Cash from Investing Activities: up 65099.47% in 2023, down 1199309.94% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$12137.0 in 2022, then soared by 60469.54% to $7.3 million in 2023, then plunged by 97.66% to $171532.0 in 2024, then plunged by 599.42% to -$856665.0 in 2025, then slumped by 120.29% to -$1.9 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.9 million, $2.8 million, and -$856665.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | -1.21 Bn |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | 131.00 Mn |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | -19.92 Mn |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | -20.68 Mn |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | -328.00 Mn |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | 331.22 Mn |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | -25.05 Mn |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | -53.37 Mn |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | 41.55 Mn |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | -1.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -1.89 Mn |
| Jan 31, 2026 | 2.77 Mn |
| Oct 31, 2025 | -856,665.00 |
| Jul 31, 2025 | 1.63 Mn |
| Apr 30, 2025 | -3.23 Mn |
| Jan 31, 2025 | 988,338.00 |
| Oct 31, 2024 | 171,532.00 |
| Jul 31, 2024 | 3.69 Mn |
| Apr 30, 2024 | -458,942.00 |
| Jan 31, 2024 | -4.76 Mn |
| Oct 31, 2023 | 7.33 Mn |
| Jul 31, 2023 | -6.18 Mn |
| Apr 30, 2023 | 2.83 Mn |
| Jan 31, 2023 | -8.20 Mn |
| Oct 31, 2022 | -12,137.00 |
| Jul 31, 2022 | -2,087.00 |
| Apr 30, 2022 | -4,361.00 |
| Jan 31, 2022 | -684.00 |
| Oct 31, 2021 | 881.00 |
| Jul 31, 2021 | -7,110.00 |